Lilly To Deliver More Proof Points In Obesity, Keep Building Pipeline In 2024
Zepbound Readouts Expected In Co-Morbidities
Research head Dan Skovronsky said it’s hard to improve upon tirzepatide, but Lilly is advancing early and late-stage obesity drugs while investigating internal and external assets in weight loss and beyond.
